A practical use of ligand efficiency indices out of the fragment-based approach: Ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors

Journal of Medicinal Chemistry

Volumn 54, Issue 3, 2011, Pages 851-857

  Tanaka, Daisuke ^a   Tsuda, Yusuke ^a   Shiyama, Takaaki ^a   Nishimura, Tamiki ^a   Chiyo, Naoki ^b   Tominaga, Yukio ^b   Sawada, Nobuyuki ^a   Mimoto, Tsutomu ^a   Kusunose, Naoto ^a  

^a Chemistry Research Laboratories   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; LEAD; LIGAND;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BIOCHEMISTRY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPOPHILICITY; METHODOLOGY; MOLECULAR SIZE; NONHUMAN; RAT; RETROSPECTIVE STUDY;

ANIMALS; DATABASES, FACTUAL; EPOXIDE HYDROLASES; HEP G2 CELLS; HUMANS; LIGANDS; MOLECULAR CONFORMATION; OXADIAZOLES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOLUBILITY; STEREOISOMERISM; UREA; YOUNG ADULT;

EID: 79851483555     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101273e     Document Type: Article

References (27)

1. Andrews, P. R.; Craik, D. J.; Martin, J. L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27, 1648-1657. (Pubitemid 15177908)
2. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002. (Pubitemid 29422500)
3. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficinecy: A useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431. (Pubitemid 38510559)
4. Abad-Zapatero, C.; Metz, J. T. Ligand efficincy indices as guide-posts for drug discovery. Drug Discovery Today 2005, 10, 464-469.
5. Fragment-Based Approaches in Drug Discovery; Jahnke, W., Erlanson, D. A., Eds.; Wiley-VCH: Weinheim, Germany, 2006.
6. Fragment-Based Drug Discovery: A Practical Approach; Zartler, E. R., Shapiro, M., Eds.; Wiley: West Sussex, U.K., 2008.
7. Reitz, A. B.; Smith, G. R.; Tounge, B. A.; Reynolds, C. H. Hit triage using efficiency indices after screening ofcompound libraries in drug discovery. Curr. Top. Med. Chem. 2009, 9, 1718-1724.
8. Imig, J. D.; Hammock, B. D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discovery 2009, 8, 794-805.
9. Marino, J. P., Jr. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr. Top. Med. Chem. 2009, 9, 452-463.
10. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 2007, 6, 881-890. (Pubitemid 350042396)
11. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
12. Hann, M. M.; Oprea, T. I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 2004, 8, 255-263. (Pubitemid 38759400)
13. Due to poor correlation between values of ACDlogP and AlogP, both were equally considered in the present work. See Supporting Information and Muchmore, S. W.; Edmunds, J. J.; Stewart, K. D.; Hajduk, P. J. Cheminformatics tools for medicinal chemists. J. Med. Chem. 2010, 53, 4830-4841.
14. Colletti, S. L.; Shen, H.; Ding, F.-X. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment. International patent WO2009/011872, 22 January 2009.
15. Shen, H. C.; Ding, F.-X.; Wang, S.; Deng, Q.; Zhang, X.; Chen., Y.; Zhou, G.; Xu, S.; Chen, H.-S.; Tong, X.; Tong, V.; Mitra, K.; Kumar, S.; Tsai, C.; Stevenson, A. S.; Pai, L.-Y.; Alonso-Galicia, M.; Chen, X.; Soisson, S. M.; Roy, S.; Zhang, B.; Tata, J. R.; Berger, J. P.; Colletti, S. L. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J. Med. Chem. 2009, 52, 5009-5012.
16. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem. 2006, 49, 6972-6976. (Pubitemid 44885985)
17. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discovery 2009, 8, 203-212.
18. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand binding efficiency: Trends, physical basis, and implications. J. Med. Chem. 2008, 51, 2432-2438. (Pubitemid 351628504)
19. Orita, M.; Ohno, K.; Niimi, T. Two "Golden Ratio" indices in fragment-based drug discovery. Drug Discovery Today 2009, 14, 321-328.
20. Nissink, J. W. M. Simple size-independent measure of ligand efficiency. J. Chem. Inf. Model. 2009, 49, 1617-1622.
21. A similar increasing trend of SILE along structure optimization was reported: Ferenczy, G. G.; Keseru, G. M. Enthalpic efficiency of ligand binding. J. Chem. Inf. Model. 2010, 50, 1536-1541.
22. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236. (Pubitemid 26399746)
23. Maestro 8.0; Schrödinger, LLC: New York, 2007.
24. Glide 4.5; Schrödinger, LLC.: New York, 2007.
25. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D.T.; Repasky, M. P.; Knoll, E.H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749. (Pubitemid 38380917)
26. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177-6196. (Pubitemid 44595196)
27. LigPrep 2.1; Schrodinger, LLC: New York, 2007.